Janux Therapeutics, Inc.
JANX
$13.15
-$0.47-3.45%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 47.10% | -5.55% | -23.37% | -97.10% | 28.12% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 47.10% | -5.55% | -23.37% | -97.10% | 28.12% |
| Cost of Revenue | 58.55% | 82.26% | 90.73% | 84.43% | 45.03% |
| Gross Profit | -60.13% | -99.02% | -124.22% | -161.46% | -47.72% |
| SG&A Expenses | -1.11% | 1.76% | -0.14% | 65.17% | 61.17% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 38.88% | 53.21% | 55.83% | 79.27% | 53.37% |
| Operating Income | -38.21% | -59.51% | -67.85% | -119.74% | -55.89% |
| Income Before Tax | -47.25% | -64.69% | -68.32% | -139.85% | -39.84% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -47.25% | -64.69% | -68.32% | -139.85% | -39.84% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -47.25% | -64.69% | -68.32% | -139.85% | -39.84% |
| EBIT | -38.21% | -59.51% | -67.85% | -119.74% | -55.89% |
| EBITDA | -38.97% | -60.80% | -69.54% | -123.60% | -57.48% |
| EPS Basic | -35.52% | -43.29% | -42.46% | -96.30% | -11.00% |
| Normalized Basic EPS | -35.50% | -43.27% | -42.45% | -96.28% | -11.00% |
| EPS Diluted | -35.52% | -43.29% | -42.46% | -96.30% | -11.00% |
| Normalized Diluted EPS | -35.50% | -43.27% | -42.45% | -96.28% | -11.00% |
| Average Basic Shares Outstanding | 9.24% | 15.31% | 18.42% | 20.04% | 24.24% |
| Average Diluted Shares Outstanding | 9.24% | 15.31% | 18.42% | 20.04% | 24.24% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |